Literature DB >> 20027676

MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma.

Michael Bernhard Pitton1, Roman Kloeckner, Sascha Herber, Gerd Otto, Karl Friedrich Kreitner, Christoph Dueber.   

Abstract

AIM: To compare the diagnostic capability of multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) for the detection of hepatocellular carcinoma (HCC) tumour nodules and their effect on patient management.
METHODS: A total of 28 patients (25 male, 3 female, mean age 67 +/- 10.8 years) with biopsy-proven HCC were investigated with 64-row MDCT (slice 3 mm native, arterial and portal-venous phase, 120 mL Iomeprol, 4 mL/s, delay by bolus trigger) and MRI (T1fs fl2d TE/TR 2.72/129 ms, T2tse TE/TR 102/4000 ms, 5-phase dynamic contrast-enhanced T1fs fl3d TE/TR 1.56/4.6, Gadolinium-DTPA, slice 4 mm). Consensus reading of both modalities was used as reference. Tumour nodules were analyzed with respect to number, size, and location.
RESULTS: In total, 162 tumour nodules were detected by consensus reading. MRI detected significantly more tumour nodules (159 vs 123, P < 0.001) compared to MDCT, with the best sensitivity for early arterial phase MRI. False-negative CT findings included nodules < or = 5 mm ( n = 5), < or = 10 mm ( n = 17), < or = 15 mm ( n = 12 ), < or = 20 mm ( n = 4 ), and 1 nodule > 20 mm. MRI missed 2 nodules < or = 10 mm and 1 nodule < or = 15 mm. On MRI, nodule diameters were greater than on CT (29.2 +/- 25.1 mm, range 5-140 mm vs 24.1 +/- 22.7 mm, range 4-129 mm, P < 0.005). In 2 patients, MDCT showed only unilobar tumour spread, whereas MRI revealed additional nodules in the contralateral lobe. Detection of these nodules could have changed the therapeutic strategy.
CONCLUSION: Contrast-enhanced MRI is superior to 64-row MDCT for the detection of HCC nodules. Patients should be allocated to interventional or operative treatment according to a dedicated MRI-protocol.

Entities:  

Mesh:

Year:  2009        PMID: 20027676      PMCID: PMC2797660          DOI: 10.3748/wjg.15.6044

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

3.  Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning.

Authors:  Hong Zhao; Jin-Lin Yao; Ying Wang; Kang-Rong Zhou
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

4.  Mortality from hepatocellular and biliary cancers: changing epidemiological trends.

Authors:  Satheesh Nair; K Shiv Kumar; Paul J Thuluvath; K S Shivakumar; K Shiva Kumar
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

5.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

6.  Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue.

Authors:  Bobby Bhartia; Janice Ward; J Ashley Guthrie; Philip J Robinson
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 8.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT.

Authors:  Bo Kiung Kang; Jae Hoon Lim; Seung Hoon Kim; Dongil Choi; Hyo Keun Lim; Won Jae Lee; Soon Jin Lee
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

10.  Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging.

Authors:  Tejas Parikh; Stephen J Drew; Vivian S Lee; Samson Wong; Elizabeth M Hecht; James S Babb; Bachir Taouli
Journal:  Radiology       Date:  2008-01-25       Impact factor: 11.105

View more
  7 in total

Review 1.  Radiation risk from medical imaging.

Authors:  Eugene C Lin
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

2.  Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Mohamad Zakarya AlAzzazy; Ayman F Ahmed; Hala Y Yousef; Samar Mohamad Shehata; Dena Abd El Aziz El Sammak; Talaat Fathy; Ahmed Ali Obaya; Eman H Abdelbary
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

Review 3.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

Review 4.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

5.  APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.

Authors:  Cher Heng Tan; Su-Chong Albert Low; Choon Hua Thng
Journal:  Int J Hepatol       Date:  2011-04-19

6.  Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?

Authors:  Bettina Maiwald; Donald Lobsien; Thomas Kahn; Patrick Stumpp
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

Review 7.  Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma.

Authors:  C G Cristea; I A Gheonea; L D Săndulescu; D I Gheonea; T Ciurea; M R Purcarea
Journal:  J Med Life       Date:  2015 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.